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Abstract: The development of separation methods for the analysis and resolution of chiral drugs
and solutes has been an area of ongoing interest in pharmaceutical research. The use of proteins as
chiral binding agents in high-performance liquid chromatography (HPLC) has been an approach
that has received particular attention in such work. This report provides an overview of proteins
that have been used as binding agents to create chiral stationary phases (CSPs) and in the use of
chromatographic methods to study these materials and protein-based chiral separations. The supports
and methods that have been employed to prepare protein-based CSPs will also be discussed and
compared. Specific types of CSPs that are considered include those that employ serum transport
proteins (e.g., human serum albumin, bovine serum albumin, and alpha1-acid glycoprotein), enzymes
(e.g., penicillin G acylase, cellobiohydrolases, and α-chymotrypsin) or other types of proteins
(e.g., ovomucoid, antibodies, and avidin or streptavidin). The properties and applications for
each type of protein and CSP will also be discussed in terms of their use in chromatography and
chiral separations.
Keywords: chiral high-performance liquid chromatography (HPLC); protein-based chiral stationary
phases; chiral recognition; chromatographic studies of drug-protein interactions; frontal analysis;
zonal elution
1. Introduction
The use of molecular chirality can be traced back to the mid-1800s in the work by Louis
Pasteur with tartaric acid [1–3]. In the late 1970s, Yoshio Okamoto synthesized a helical polymer of
triphenylmethyl methacrylate and used this material to develop chromatographic columns that could
be used for chiral separations [4]. Since that time, significant effort has been aimed at creating chiral
stationary phases (CSPs) that can be used in chromatography for the separation and analysis of chiral
compounds [3–9].
Many pharmaceutical agents are chiral molecules [7,10–13]. Although these compounds are often
sold as racemic mixtures, about two-thirds of the drugs that are currently available commercially are
chiral [7,14]. Even though the two enantiomers of a drug will have most of the same physical properties,
they may vary significantly in how they interact with a biological system, possibly leading to different
levels of activity or side effects [10,11,15]. For example, S-ibuprofen is over 100 times more potent than
R-ibuprofen at cyclooxygenase 1 and 2 inhibition, and R-thalidomide is a sedative while S-thalidomide
is a teratogen. In addition, the S-enantiomers of barbiturates such as pentobarbital, hexobarbital,
and mephobarbital are sedatives/hypnotics while the R-enantiomers tend to be inactive [10,15].
These differences have made it necessary to provide pure enantiomers in pharmaceutical formulations
and/or to determine the effects the separate enantiomers may have in the body [7,9]. This, in turn,
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has led to the need for analytical methods and preparative techniques that can be used to analyze and
separate chiral compounds in pharmaceutical samples [7,9].
Several methods have been employed for the chiral separation of drugs and amino acids for
chemical analysis. These methods have included gas chromatography, thin layer chromatography,
high-performance liquid chromatography (HPLC), supercritical fluid chromatography, and capillary
electrophoresis [6,9,16–18]. Methods based on HPLC have been of particular interest [6,9,17–19].
Many types of stereoselective binding agents have been used to prepare CSPs for HPLC. The use of
these agents in a liquid chromatographic system can be viewed as a type of affinity chromatography
or high-performance affinity chromatography (HPAC) [3–9]. Examples of such binding agents
have included proteins, polysaccharides, macrocyclic antibiotics, and ion-exchange ligands, among
others [5,6,17,19–21].
Many proteins have the potential to discriminate between the separate forms of a chiral compound.
This is the case because proteins are also chiral in nature in terms of both their primary structure
(i.e., being made of L-amino acids) and their secondary or higher order structures [17]. Various types
of proteins have been immobilized and used to make CSPs for HPLC, ranging from enzymes to
serum transport proteins and glycoproteins. Some common examples of these proteins are shown in
Table 1 [17,18,20–26]. These separations are performed based on differences in the binding strength
and amount or number of binding sites for chiral compounds with the protein [3]. Advantages of using
protein-based CSPs include their tendency to be able to work with a broad range of chiral compounds,
their ability to be used with aqueous mobile phases, and their ability to directly analyze most chiral
compounds without the need for derivation [17,19,22,27]. However, protein-based CSPs can also have
a low loading capacity, be expensive to prepare, and have limited stability, which makes these of
greater interest for analytical work than for preparative separations [17,19,28,29].
Table 1. Examples of proteins that have been used as chiral stationary phases for liquid chromatography
a. pI: isoelectric point; CBH: cellobiohydrolase.
Type of Protein Molecular Mass (kDa) Isoelectric Point, pI
Serum transport protein
α1-Acid glycoprotein (AGP) 41 2.7
Human serum albumin (HSA) 66 4.7
Bovine serum albumin (BSA) 66.5 4.7–4.9
Enzymes
Cellobiohydrolases
CBH I 60–70 3.9
CBH II
α-Chymotrypsin 25 8.1–8.3
Lysozyme 14 11
Penicillin G acylase 90 6.4
Other proteins
Antibodies (e.g., immunoglobulin G) ~150 4.4–10
Avidin 68 10
Ovomucoid 28.8 3.9–4.5
Streptavidin 60 5
a This table is based on information that was obtained from Refs. [18,23,24].
This review will discuss how chromatographic methods have been used to examine and
characterize protein-based chiral separations. Tools that have been used in such work will first
be considered, including zonal elution, frontal analysis, and kinetic methods of analysis. Methods
and supports that have been employed for preparing protein-based CSPs will then be considered.
The properties and applications for several specific types of protein-based CSPs will then be examined.
This will include CSPs that employ various types of serum transport proteins and enzymes, as well as
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binding agents such as antibodies and avidin/streptavidin. The relative advantages for each type of
CSP will be discussed, along with information that has been obtained through chromatography on
these materials and their ability to bind and separate chiral agents.
2. Chromatographic Methods Used to Study Protein-Based Chiral Separations
2.1. Zonal Elution
Zonal elution has been widely used in HPLC-based chiral separations [30–32]. This method
can also be employed to measure the separation factors and resolution of solutes on CSPs
(see Figure 1) [33–35]. Another use of zonal elution is to obtain information on the interactions
between an injected solute and an immobilized protein. This approach can provide information on the
strength of solute–protein binding, the changes in binding that occur as the mobile phase composition
or temperature is changed, the location and types of binding sites for the solute on the protein, and
the effect of altering the solute or protein structures on the interactions of these agents [32,36,37].
Zonal elution can be used to provide this information when a small amount of the solute of interest
is injected onto a protein-based CSP in the presence of a competing agent or a mobile phase with a
known composition and temperature. The retention factor for the solute is then measured and the
change in this value is examined as the conditions used within the column are varied [38,39].
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Figure 1. Chromatograms obtained by zonal elution for the chiral separation of D- and
L-tryptophan on high-performance liquid chromatography (HPLC) columns containing human
serum albumin (HSA) immobilized to sulfhydryl-reactive silica that had been activated by using
succinimidyl 4-(N-maleimidomethyl) cyclohexane-carboxylate (SMCC) or succinimidyl iodoacetate
(SIC). Reproduced with permission from [35]. Copyright American Chemical Society, 2007.
For a solute or analyte (A) that is injected onto a column that contains an immobilized protein,
the retention factor for the analyte (k) can be related to the number of binding sites for the analyte on
the protein and the equilibrium constants for the analyte at these sites. Equation (1) is an example of
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this relationship for a protein-based CSP with a series of independent binding sites (1 through n) for
the analyte [40].
k = (KA1n1 + · · ·+ KAnnn)mL/VM (1)
In this equation, the terms KA1 through KAn are the association equilibrium constants for the
analyte at each type of binding site in the column, n1 through nn represent the relative amount or
moles for each type of site, mL is the total moles of binding sites that are present, and VM is the column
void volume. According to Equation (1), the retention of the analyte can provide both qualitative and
quantitative information on a solute–protein interaction. This includes the relative amount of active
binding sites in the column (i.e., mL/VM) and the overall binding strength of these sites (i.e., KA1n1
+ . . . + KAnnn) [32]. The advantages of using zonal elution to obtain this data include its need for
only a small amount of the analyte and its ability in some cases to study more than one analyte per
injection [39]. In addition, this method can be used with standard HPLC systems and often requires
only short analysis times [39].
Another application of zonal elution has involved the development of quantitative
structure-retention relationships (QSRRs) that characterize the binding of drugs and other solutes
to protein-based CSPs [41–43]. In this type of study, a set of retention parameters are acquired for a
series of analytes and compared to various structural descriptors for these solutes to see which of
these factors influence retention [42]. The resulting QSRRs can then be used to predict the retention
of a related solute, to investigate the molecular mechanism of the chiral separation, or to compare
the retention properties of CSPs [42]. Specific applications of this approach have involved its use to
examine the retention of benzodiazepine derivatives on human serum albumin (HSA) columns [43],
to study the stereoselective separations of chiral solutes on a bovine serum albumin (BSA) column,
and to characterize the chiral recognition of columns produced with BSA fragments [41].
Competitive binding studies can be used in zonal elution to determine which types of sites
are binding to a given form of a drug and to estimate the equilibrium constants at these individual
sites [34,44–47]. In this approach, a small amount of the analyte is injected onto a column that contains
a protein (or other type of binding agent) and in the presence of mobile phases that have various
known concentrations of a competing agent, I [34,44,45]. The retention factor observed for the analyte
(kA) should change as the concentration of the competing agent, [I], is varied if both A and I are binding
to the same sites in the column. For instance, Equation (2) shows how kA will change with [I] for
a system in which A and I have competition at a single type of site and A has no other sites in the
column [34,44,45]:
1
kA
=
KIVM [I]
KAmLtot
+
VM
KAmLtot
(2)
In this equation, KI or KA is the association equilibrium constant for the binding of I or A at their
common site, and mLtot is the total moles of active binding sites at which A and I compete [34,44,45].
This method has been used to examine the interactions between D- and L-tryptophan on HSA, as well
as the interactions between these amino acid enantiomers and R-warfarin [45]. Related equations have
been employed to examine multisite binding and allosteric interactions between drug enantiomers
and other drugs or solutes on HSA columns [44,48–52].
Another use of zonal elution has been to evaluate the efficiency of protein-based CSPs, as can be
done through band-broadening measurements [53–58]. It has been found that the efficiency of these
columns can be affected by factors such as temperature, the amount of immobilized protein, the flow
rate, and the mobile phase composition [53–57]. This approach has been used with HSA monoliths
to study and optimize the chiral separation of R- and S-warfarin or D- and L-tryptophan [54,56].
This approach has also been utilized to examine the chiral separation for R- and S-warfarin or R- and
S-propranolol on various columns containing alpha1-acid glycoprotein (AGP) [54,56].
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2.2. Frontal Analysis
Frontal analysis is another chromatographic approach that has been used to examine the chiral
interactions of drugs and other solutes with proteins [31,33,59]. In this method, a solution containing a
known concentration of an analyte is continuously applied to a column that contains an immobilized
protein or binding agent. The amount of the analyte that passes through the column is then monitored
as a function of the amount of time or mobile phase volume that is used for application of the
analyte [32,60,61]. As binding sites in the column become occupied by the analyte, a breakthrough
curve is observed (see Figure 2) [32,60,61]. This experiment is repeated at several known concentrations
of the analyte. If fast association and dissociation are present between the analyte and the protein,
the mean position of each breakthrough curve (i.e., the breakthrough time or volume) can be used to
obtain information on the thermodynamics of the interaction. This is done by fitting the results to
binding models, such as those given in Equations (3) and (4) [32,62,63]:
mLapp =
mLtotKa [A]
1+ Ka [A]
(3)
mLapp =
mL1Ka1 [A]
1+ Ka1 [A]
+
mL2Ka2 [A]
1+ Ka2 [A]
(4)
Equation (3) describes the interaction of analyte A with a single type of saturable binding site,
in which mLtot is the total moles of binding sites that are present for the analyte, and Ka is the association
equilibrium constant for the analyte at these sites [32,60,61]. Equation (4) applies to a case in which
the column contains two groups of saturable sites for the analyte. In this latter situation, mL1 and
mL2 are the total moles of sites 1 and 2, respectively, and Ka1 and Ka2 are the association equilibrium
constants for the analyte at these sites [32,60,61]. Such models have been applied in the investigation
of the equilibrium constants and number of binding sites for many chiral drugs with proteins such as
HSA and AGP [34,45,57,64,65]. The same type of approach can be utilized with other binding models,
as has been demonstrated in frontal analysis studies that have examined the interactions of R- and
S-propranolol with low density lipoprotein and related binding agents [66–69].
An advantage of using frontal analysis to study protein-based CSPs is that this method can
simultaneously provide information on both the equilibrium constants and the number of binding
sites that are involved in the interaction of a solute with this type of column [32,60,61]. Frontal analysis
can also be used with various types of supports and detection methods, including those used in either
low- or high-performance liquid chromatography [32]. However, this approach does tend to require a
larger amount of solute than zonal elution and often takes longer to perform because of the need for
experiments at multiple concentrations of the analyte [32].
To characterize a protein-based CSP, frontal analysis is typically used to study the binding by
separate chiral solutes to the column. The information that is obtained for the various chiral forms
can be used to examine the retention mechanism and optimize the separation of these forms on the
CSP [6,31,57]. Examples of such work include frontal analysis studies that have been conducted with
R- and S-warfarin or D- and L-tryptophan on HSA columns (see Figure 2) [57,65]. Frontal analysis
was utilized in these two cases to determine the binding strength and amount of binding sites for
each enantiomer on the protein-based CSPs. Based on this information, it was possible to predict the
behavior of these analytes during chiral separations [57,65].
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Figure 2. Frontal analysis results obtained for R-warfarin on an immobilized human serum albumin
(HSA). The breakthrough curves in (a) were obtained at 4 ◦C and using R-warfarin concentrations
(from left-to-right) of 1.50, 1.30, 1.10, 0.76, 0.55, 0.33 and 0.22 µM. The plots in (b) were obtained
when such data were acquired at various temperatures (4–45 ◦C) and analyzed according to a
double-reciprocal form of Equation (3). Reproduced with permission from [65]. Copyright American
Chemical Society, 1994.
2.3. Kinetic Studies
The rate of a solute–protein interaction is another factor to consider in characterizing the separation
of chiral drugs. This information can be helpful in examining the mechanism of a protein-based chiral
separation and in optimizing such a separation [53,70–72]. Several chromatographic approaches have
been used to examine the kinetics of drug–protein interactions. These methods include plate height
measurements and the peak decay method [53,70–73].
Plate height and band-broadening measurements have been used in several studies to examine the
rate of a drug interaction with an immobilized binding agent such as a protein [53,71–76]. For instance,
plate height measurements have been used to obtain the dissociation and association rate constants for
R- and S-warfarin or D- and L-tryptophan on columns containing immobilized HSA (see Figure 3) [53,72].
This kinetic information was obtained as conditions such as the mobile phase composition and
temperature were varied and were used to optimize chiral separations for the given solutes on
HSA columns. The temperature data were further employed to determine the changes in enthalpy,
entropy, and total free energy that occur during the formation of an activated complex between each
enantiomer and HSA [53,72]. Plate height measurements have also been utilized in a closely related
method known as peak profiling to examine the interactions and separation of chiral phenytoin
metabolites on an HSA column [71].
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Figure 3. Use of frontal analysis and band-broadening measurements to measure the effect of
temperature on the (a) Association equilibrium constants (Ka), (b) Dissociation rate constants (kd)
and (c) Association rate constants (ka) for the interactions of D-tryptophan () and L-tryptophan (#)
with a column containing immobilized human serum albumin (HSA). Reproduced with permission
from [53]. Copyright Elsevier, 1997.
The peak decay method is another technique that has been used to study the kinetics for chiral
drugs on columns containing immobilized proteins [73,76–78]. In this method, the target compound is
first ap lied to the column, followed by a switch to flow rate and mobile phase conditions that allow
elution of this target as soon as it dissociates from the immobilized binding agent. If this experiment is
carried out under the proper column size and flow rate conditions, release of the bound target from
the column should follow a pseudo-first-order decay that can be used to obtain the dissociation rate
constant for the target from the immobilized binding agent [73,76–78]. A noncompetitive peak decay
method was used with small HSA columns to examine the dissociation rate of R- and S-warfarin [70].
This work included an evaluation of how factors such as the column size, the amount of applied
analyte, the flow rate, and particle size of the support affected these measurements [70]. In addition to
drug enantiomers, the peak decay method has been used to determine the dissociation rates for drugs
such as imipramine, cisplatin, and lidocaine from HSA or AGP [70,78,79].
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3. Preparation of Protein-Based CSPs
3.1. Supports Used in Protein-Based CSPs
Various support materials have been employed in protein-based CSPs. Examples of these
materials are agarose, silica, polymeric supports, and zirconia particles [18]. Agarose was used as early
as 1973 to immobilize BSA for chiral separations [17,80]. Silica particles and related materials have also
been used as supports in protein-based CSPs. The efficiency and good mechanical stability of these
supports have been valuable in creating CSPs for use in HPLC systems [3,17,18]. Silica is generally
limited to a pH range of 2–8 in these applications; however, this has not been a major issue in work with
protein-based CSPs, which are often used at a neutral pH or over a pH range of 3–8 [17]. Silica monoliths
have also been considered for use in protein-based chiral separations [54,59,81,82]. This type of
monolith can be obtained commercially and is prepared through the hydrolysis of alkoxysilane
precursors such as tetramethoxysilane and methyltrimethoxysilane, followed by condensation to yield
a silica support [83–86].
Organic polymer-based monoliths have been employed in chiral separations [54,56,59,81,87–91].
A number of previous reports have prepared organic monoliths based on the use of glycidyl
methacrylate (GMA) and ethylene dimethyacrylate (EDMA) [54,56,59,87]. These monoliths are
relatively easy to prepare and can have high permeability and low back pressures, along with good
efficiencies [81,92]. It is also possible to use these monoliths with various immobilization schemes to
create protein-based CSPs [81,92].
Both AGP- and HSA-based CSPs have been prepared by using supports such as silica particles,
silica monoliths, and GMA/EDMA monoliths and compared through the methods of frontal analysis
and zonal elution [54,59,93,94]. Some typical results are shown in Table 2 [54]. In general, higher
protein content has been obtained for these CSPs when using a silica monolith versus silica particles or
GMA/EDMA monoliths. This higher protein content tends to result in higher retention and greater or
comparable resolution for some chiral solutes when using AGP or HSA in the silica monoliths [54,59].
Zirconia is another material that has been used in protein-based CSPs [18,95,96]. Advantages of
using porous zirconia as a chromatographic support include its good mechanical, chemical, and thermal
stabilities [18,95,96]. This material is also stable over a pH range of 1–14 [18,95]. Zirconia has been
considered for use in a BSA-based CSP [96]. A zirconia-containing mixed oxide (i.e., magnesia-zirconia)
has also been used in BSA-based CSPs, with the latter type of support being reported to have a larger
surface area, and better pore size distribution and pore structure than bare zirconia [95].
3.2. Development and Evaluation of Protein Immobilization Methods
Gentle methods are usually desirable for immobilization when making a protein-based CSP to
maintain the conformation of the protein and its ability for chiral discrimination [18]. A number of
immobilized proteins have been employed in CSPs, as is shown in Table 1 [18,23–26]. More details
on each of these proteins are provided in Section 4. Commercial CSPs are available that make use of
the proteins BSA, HSA, and AGP, as well as enzymes such as cellobiohydrolase I (CBH I) [17,18,20,97].
Immobilization methods for preparing these and other protein-based CSPs have included physical
adsorption, covalent immobilization, and encapsulation [3]. The evaluation of methods for preparing
protein-based CSPs has often been performed by using chromatographic techniques such as frontal
analysis and zonal elution, as described in Section 2 [33–35,58,59].
Separations 2016, 3, 27 9 of 26
Table 2. Properties of AGP immobilized to various supports and chromatographic parameters of these
supports for R- and S-propranolol a.
Type of Support Silica Monolith Silica Particles GMA/EDMA Monolith
Protein content (nmol/g support) 1800 (± 40) 490 (± 20) 250 (± 10)
Protein coverage (nmol/m2) 5.8 (± 0.2) 4.9 (± 0.2) 3.6 (± 0.1)
Retention factor, k
31.1 (± 0.4) (R) 11.6 (± 0.2) (R) 4.53 (± 0.06) (R)
37.2 (± 0.4) (S) 13.7 (± 0.3) (S) 6.86 (± 0.05) (S)
Separation factor, α 1.20 (± 0.01) 1.18 (± 0.05) 1.51 (± 0.06)
Resolution, Rs 1.11 (± 0.03) 0.55 (± 0.03) 0.79 (± 0.03)
a Adapted with permission from [54]. Copyright Elsevier, 2007.
3.2.1. Physical Adsorption
Physical adsorption typically involves the simple adsorption of a binding agent to a surface [98].
Physical adsorption based on ionic and/or hydrophobic interactions has been employed to immobilize
proteins such as lysozyme and avidin onto silica particles and monoliths to form CSPs, as well as in
fused-silica capillaries [98–103]. Adsorption onto silica has also been used to make stationary phases
containing BSA or its fragments [104], α-chymotrypsin [105], lysozyme [98], and avidin [99,100,106].
In addition, BSA has been adsorbed onto zirconia and used as a CSP [96]. In this last example,
adsorption at pH 4.4 gave a greater amount of adsorbed protein and stronger retention than when
pH 6.9 was utilized; however, a support made at pH 6.9 gave better stereoselectivity [96].
Anion-exchange silica materials and polyethylene hollow fiber membranes are other supports that
have been utilized to adsorb BSA and HSA for use in CSPs [101,102].
The major advantage of physical adsorption is its simplicity. This method is generally carried out
by simply pumping a protein solution through a column under appropriate pH and solution conditions
for adsorption [18]. Such a technique can be employed for the rapid assessment of new protein
candidates for use in CSPs [18]. One drawback of this immobilization method is that CSPs that are made
by physical adsorption can have stability problems due to the presence of weak interactions between
the adsorbed protein and support [18]. In some cases, the optimum conditions for a stereoselective
separation may lead to the loss of an adsorbed protein over time, possibly requiring the use of
crosslinking to prevent this loss [17].
3.2.2. Covalent Immobilization
Covalent immobilization is the most common approach for preparing protein-based CSPs and can
result in supports with good long-term stabilities [18,107]. Many techniques have been used to couple
proteins to supports in CSPs. Some of these techniques are the Schiff base method (i.e., reductive
amination), the N-hydroxysuccinimide (NHS) method, the carbonyldiimidazole (CDI) method, the
epoxy method, the ethyl dimethylaminopropyl carbodiimide (EDC) method, and the tresyl chloride
method, as well as others [17,18,105,107]. Figure 4 shows a few examples of these methods.
A number of protein-based CSPs have been prepared using the Schiff base method. This is often done
by taking a diol-containing support, oxidizing this support to form aldehyde groups, and then allowing
these aldehyde groups to combine with free amine groups on a protein and in the presence of sodium
cyanoborohydride as a mild reducing agent [18,55,71,108–110]. The Schiff base method has often
been employed for preparing columns containing HSA or BSA as CSPs [22,45,53,57,59,65,72,104,111].
A modified form of the Schiff base method has been used to immobilize serum albumins to
amine-containing silica that has been activated with glutaraldehyde [95,112]. Similar methods have
also been used to immobilize antibodies onto silica for use in chiral separations [113,114].
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The NHS method involves the use of a support that has been activated with a homo- or
heterobifunctional agent such as N,N′-disuccinimidyl carbonate (DSC), N,N′-disuccinimidyl suberate
(DSS), succinimidyl 4-(N-maleimidomethyl) cyclohexane-carboxylate (SMCC), or succinimidyl
iodoacetate (SIC) [107]. DSC has been used to activate amine-derivatized silica for preparing various
protein-based CSPs [3,17,33,35,109,115–118]. One report evaluated the binding of carbamazepine
with HSA that had been immobilized by the Schiff base method or a DSC-based NHS method; these
two approaches gave HSA columns with comparable binding constants and activities, but the NHS
method gave less non-specific binding for carbamazepine [33]. However, CSPs that were prepared
with amyloglucosid s and using DSC-activated sili show d poor stability when compared o a
support made by the Schiff base method [110]. DSS has been used as an activating agent to immobilize
HSA and vidin to aminopropyl silica for use as CSPs [109,115,116]. In one study, the etention and
enantioselectivity of an avidin-based CSP made with DSS were foun to be higher than the results that
were obtained w en usi g DSC [116].
The epoxy, CDI, and tresyl chloride methods are other approaches for immobilizing proteins
through their amine groups [18,105,119–121]. The immobilization of α-chymotrypsin to silica
has been examined when using the epoxy, tresyl chloride, and Schiff base methods [105].
The α-chymotrypsin-based CSP that was prepared by the epoxy method gave the highest enzyme
content and the largest stereoselectivities in this group; a similar loading of the enzyme was observed
in the other two methods, with the tresyl chloride method giving a support with lower stereoselectivity
than that obtained with the Schiff base method [105]. Both BSA and HSA have been immobilized
to diol-bonded silica particles by the CDI method, giving a final protein content that was two-fold
higher than that obtained with the epoxy method [120]. The tresyl chloride method has also been
used to immobilize BSA to silica, giving a comparable protein content to that obtained with the CDI
method [120]. However, it has been noted for some drugs and solutes that the CDI method can result
in greater non-specific binding than the Schiff base or NHS methods [33].
CSPs can be prepared by using other functional groups on proteins for immobilization.
For instance, a protein can be coupled to a support through carboxylate groups by using the EDC
method [17,122]. This method has been used to immobilize CBH I to amine-containing silica [122].
The same method has been employed for the immobilization of penicillin G acylase (PGA) [123].
Immobilization can also be achieved through the use of sulfhydryl groups on a protein. For instance,
HSA has been immobilized through its lone free sulfhydryl group to amine-derivatized silica, which
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was activated by using SMCC or SIC [35]. HSA-based CSPs prepared by these methods were found to
have comparable or improved activity and stability to HSA supports that were made by the Schiff base
method [35]. In addition, it is possible to use carbohydrate groups to immobilized glycoproteins
for use as CSPs [34,54]. An example is the use of mild oxidation to generate aldehyde groups in
the carbohydrate chains of AGP, followed by the coupling of these groups with hydrazide-activated
supports such as silica particles, silica monoliths, or GMA/EDMA monoliths [34,54].
3.2.3. Encapsulation and Entrapment
When covalent immobilization is used, effects such as multisite attachment or the improper
orientation of a protein can result in an actual or apparent loss of activity for this binding agent [107].
These effects can be avoided by instead using encapsulation or entrapment. These are non-covalent
immobilization techniques based on the physical containment of a protein within a support [83–85,107].
Several reports have employed sol-gel encapsulation to prepare monoliths that contained BSA or
ovomucoid for use as CSPs in capillary electrochromatography (CEC) [83,84,86]. This method has also
been used to prepare a sol-gel/organic hybrid composite material containing encapsulated BSA [85].
An alternative method based on entrapment was recently reported in which HSA and AGP were
entrapped in hydrazide-activated silica by using mildly oxidized glycogen as a capping agent [124–126].
This method has been used with both normal HSA and glycated HSA and has been found to give
essentially full activity for these proteins in their binding with chiral solutes such as R-warfarin and
L-tryptophan [125].
4. Chromatographic Studies of Protein-Based CSPs
4.1. Serum Transport Proteins
A number of serum proteins play a crucial role in transporting endogenous and exogenous
compounds in the bloodstream, such as drugs, hormones, fatty acids, and metal ions [3,111,127].
Many of these interactions are also stereoselective in nature [3,128]. This feature has made serum
transport proteins such as HSA, BSA, and AGP of interest for use as CSPs and in chromatographic
studies of drug–protein interactions [3,128].
4.1.1. Human Serum Albumin and Bovine Serum Albumin
HSA is the most abundant protein in human plasma (concentration, 30–50 mg/mL). This protein
consists of 585 amino acids and has a molecular mass of 66.5 kDa [3,127]. BSA is the type of serum
albumin found in cattle [129] and is closely related to HSA, with a molecular mass of 66.2 kDa [3].
Both HSA and BSA are globular proteins with single polypeptide chains that are stabilized by
17 disulfide bridges [3].
HSA and BSA have two major drug binding sites that are often referred to as Sudlow sites I
and II [130,131]. Sudlow site I (i.e., the warfarin-azapropazone site) is formed by a hydrophobic
pocket in subdomain IIA of HSA [130,131]. Warfarin is commonly used as a probe for this site [132].
Sudlow site II (i.e., the indole-benzodiazepine site) is located in subdomain IIIA. Diazepam,
L-tryptophan, and ibuprofen have all been used as probes for this region [133]. HSA and BSA
also contain several binding regions for other solutes, such as fatty acids, metal ions, and other types
of drugs or organic compounds [3].
The various sites on these proteins and the relatively broad range of solutes that can bind to
these regions have made BSA and HSA of interest in obtaining chiral separations [3,17]. The use
of serum albumins as binding agents for chiral separations has been widely examined in terms of
the immobilization methods, types of supports and chromatographic conditions that can be used in
such work [3,17,20]. Examples of chiral compounds that have been separated and studied by HSA- and
BSA-based CSPs have included coumarins (e.g., R/S-warfarin) [119], benzodiazepine derivatives [43,134],
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barbiturates [135], benzothiadiazeines [135], α-arylpropionic acids (e.g., R/S-ibuprofen) [44], and amino
acids (e.g., D/L-tryptophan) or hormones (e.g., D/L-thyroxine) and related derivatives [104,136–138].
Chromatography has been used to carry out thermodynamic and kinetic studies on the binding
of chiral solutes such as R- and S-warfarin and D- and L-tryptophan with immobilized HSA columns
(see Figures 2 and 3) [44,45,53,57,65,72]. For R- and S-warfarin, frontal analysis and zonal elution
competition experiments indicated that these two enantiomers were binding to the same region on
HSA but with a slightly higher binding capacity being observed for R-warfarin and a larger change in
enthalpy being seen for S-warfarin [65]. Plate height measurements have been used to examine the
interaction kinetics of R- and S-warfarin with immobilized HSA [72]. The dissociation rate constants
for these interactions have been found to increase as the temperature is raised from 4 to 45 ◦C, with the
value for R-warfarin going from 0.06 to 1.9 s−1 and the value for S-warfarin increasing from 0.06 to
0.36 s−1 [72]. The combined results obtained from these studies have further indicated that the chiral
separation of R- and S-warfarin on an HSA column can be altered by varying the temperature [65,72].
Similar experiments employing frontal analysis and zonal elution have been used to investigate
the binding of D- and L-tryptophan with immobilized HSA [45,53,57]. It has been found that these
enantiomers bind to single but distinct sites on HSA, with L-tryptophan binding to Sudlow site II and
D-tryptophan indirectly interacting with Sudlow site I [45,53,57]. The association equilibrium constants
for D- and L-tryptophan with HSA were measured by chromatographic methods at temperatures
ranging from 4 to 45 ◦C, with zonal elution studies also being used to estimate the dissociation
and association rate constants for these interactions as a function of temperature, pH, ionic strength
and solvent polarity [53,57]. In addition, studies with chemically-modified HSA have shown that
HSA’s lone tryptophan residue (Trp-214) affects the stereoselective binding of HSA for solutes such as
warfarin [64].
It has been found in chromatographic studies that the pH of the mobile phase can affect the
retention and stereoselectivity of serum albumin-based CSPs. For acidic compounds like warfarin and
carboxylic acids, a decrease in pH of a serum albumin-based CSP can lead to an increase in retention
and a decrease in stereoselectivity [135,139]. For basic compounds that contain an amine group and are
aromatic amino acids (e.g., D- and L-tryptophan), an increase in both the retention and stereoselectivity
is observed on a serum albumin column when there is an increase in pH [3]. Ionic strength can also
influence the retention of chiral compounds on these columns but does so in a complex manner because
both electrostatic and hydrophobic interactions are affected when the ionic strength is altered [3,139].
Furthermore, the presence of an organic modifier such as 1-propanol can be used to adjust the retention
and separation of chiral solutes on such columns [3,55,56].
In addition to supports like silica particles and agarose [3,17,140], monoliths have been used in
serum albumin-based chiral separations [56,59,141,142]. For instance, an HSA-based CSP was made
using a silica monolith and evaluated for its ability to bind and separate the enantiomers of warfarin,
tryptophan, and ibuprofen; the results were then compared with those obtained on columns that
contained HSA on silica particles or within GMA/EDMA monoliths [59]. Silica monoliths have also
been modified with BSA and gold nanoparticles. This type of CSP was employed in capillary CEC to
separate phenylthiocarbamyl amino acids [141]. Two versions of the Schiff base method were used to
immobilize BSA onto silica monoliths for use in CEC, with these supports being compared for their
ability to separate D- and L-tryptophan [142]. A GMA/EDMA monolith that contained HSA in affinity
microcolumns was optimized and employed in chiral separations, making it possible to separate the
enantiomers of warfarin and tryptophan within only 1.5–6.0 min [56].
A number of other supports and column formats have been used to make serum albumin-based
CSPs. Silica that contained both macropores and mesopores was used to immobilize BSA and tested for
its ability to separate D- and L-tryptophan [143]. A chip-based column was made by placing dopamine
and graphene oxide on the inner wall of an open-tubular capillary, with BSA then being immobilized
to this coating. This column was used in CEC for the separation of D/L-tryptophan, D/L-threonine
and a chiral dipeptide [144]. An HSA-based CSP has been used with affinity microcolumns and
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ultrafast affinity extraction to simultaneously measure the free, or non-protein bound, fractions of
R- and S-warfarin in serum and to study the interactions of these enantiomers with soluble HSA [55].
Another study used an HSA-based CSP made on a GMA/EDMA monolith to study the oxidation of
D-tryptophan by the enzyme D-amino acid oxidase (see Figure 5) [87].
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[146,147,152]. This protein is believed to have one wide and flexible drug-binding region that is 
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Thermodynamic studies have been conducted by chromatography and with immobilized AGP 
to examine the interactions of R- and S-propranolol with this protein [34,58,154]. The binding of both 
enantiomers to AGP was found to be mainly an enthalpy-driven process [34]. In addition, frontal 
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a alysis ex eri ents have suggested that the interaction of R- and S-propranolol with AGP followed a
saturable/nonsaturable mixed-mode model, with the saturable site having an equilibrium constant of
(1.1 ± 0.6) × 106 M−1 for R-propranolol and (1.4 ± 0.7) × 106 M−1 for S-propranolol at 37 ◦C [154].
Several reports have employed commercial AGP-based CSPs to evaluate the effects of changing
the mobile phase composition and column temperature on the resolution or retention of various chiral
solutes [155,156]. Altering the mobile phase pH and column temperature can be used to control the
elution order of some chiral solutes and to resolve multiple chiral compounds by using gradient
elution [155]. The use of organic modifiers such as methanol, ethanol, propanol, and tertiary alcohol
additives has also been investigated in terms of its effects on the stereoselectivity of AGP columns [156].
Commercial AGP columns have been used for the separation of many chiral
compounds [154,157–164]. For example, chiral separations have been achieved by using these
columns for atenolol, citalopram, warfarin, verapamil, norverapamil, atropine, and vinca alkaloid
analogues [157–161]. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has been
used with AGP columns for the stereoselective separation and quantitation of drugs such as
methadone [162] and ornidazole [163].
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Work has also continued in the development of new methods and supports for preparing
AGP-based CSPs [54,58]. One type of AGP-based CSP was prepared by mildly oxidizing the
carbohydrate chains on AGP and using these modified residues to immobilize this glycoprotein
onto hydrazide-activated silica [34,58]. A similar approach has been used to prepare CSPs in which
AGP was immobilized to monoliths based on silica or GMA/EDMA [54].
4.2. Enzymes
4.2.1. Penicillin G Acylase
PGA is an N-terminal nucleophile hydrolase that is widely present in bacteria, yeast, and
fungi [23,165]. Mature PGA from E. coli is a heterodimer of 20.5 kDa and 69 kDa subunits that
contain 209 and 557 amino acids, respectively [23]. PGA is often used in the pharmaceutical industry
for hydrolytic cleavage of the acyl chain of penicillin G [23,165,166]. However, this enzyme has also
been found to be useful as a CSP for a variety of acidic aromatic compounds because of its binding
specificity for acyl groups [165,166]. Other attractive features for PGA as a chiral binding agent are its
low cost and availability in a highly pure form [123].
PGA has been studied in several reports as a possible CSP. For instance, the chiral recognition
mechanism of PGA has been examined, by chromatography and other methods, for a series of
2-aryloxyacetic acids [166,167]. PGA has been immobilized to silica through amine or carboxylate
groups and employed in an HPLC system for both hydrolyzing penicillin G and carrying out a chiral
separation on the products [123]. Another report used a PGA-based silica monolith in capillary liquid
chromatography for the chiral resolution of arylpropionic acids such as ketoprofen [168].
4.2.2. Cellobiohydrolases
Cellobiohydrolases (CBHs) are enzymes found in fungal cellulose systems that have the ability
to hydrolyze β-1,4-glycosidic bonds [17,169]. The fungus Trichoderma reesei can produce two major
types of CBHs (i.e., CBH I and II), both of which are naturally N- and O-glycosylated [169]. Of these
two types, CBH I has been employed the most as a chiral selector. This enzyme has been used in
chiral separations to resolve acidic, basic, and neutral compounds [3,17,170]. CBH I consists of nearly
500 amino acids that make up a large core, a small cellulose-binding domain, and a flexible connecting
arm [17,170–172]. The catalytic domain of the core is the area that provides the chiral selectivity for
this enzyme [3,173,174].
The largest stereoselectivity for CBH I has been observed in the separation of β-blockers like
propranolol, alprenolol, oxprenolol, and metoprolol [3,17]. This observation agrees with the fact that
propranolol and alprenolol can inhibit CBH I stereoselectively, with the S-enantiomers having stronger
inhibitory effects and affinity than the R-enantiomers [174]. A number of reports have used commercial
CBH-based CSPs with LC and MS detection [169,175,176]. For example, a CBH-based CSP has been
used with LC-MS/MS to analyze 56 drug biomarkers in wastewater, including 18 pairs of enantiomers
for drugs such as amphetamine, methamphetamine, 3,4-methylenedioxy-methamphetamine, and their
metabolites [176].
4.2.3. α-Chymotrypsin
α-Chymotrypsin (sometimes referred to as “α-CHT” or “ACHT”) is a digestive enzyme and
serine protease [3]. This enzyme can hydrolyze a peptide chain on the C-terminal side of residues
that contain aromatic amino acids (e.g., tyrosine, phenylalanine or tryptophan) [3]. This enzyme has
three polypeptide chains and consists of a total of 241 amino acids [177]. The substrate-binding site of
this enzyme is composed of a hydrophobic pocket and a hydrolytically active site that is formed by
Ser 195, His 57, and Asp 102 [178].
This enzyme has been covalently immobilized to silica and used as a CSP for the stereoselective
resolution of various amino acids, amino acid derivatives, and dipeptides [179]. Aromatic amino acids
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such as tyrosine, phenylalanine, and tryptophan, which are recognized by the substrate-binding site of
α-chymotrypsin, have been the main targets of interest in these studies [3,17]. It has been found that the
O- and N-derivatives of these amino acids (e.g., methyl esters or amides) can also be resolved by using
this type of CSP [105]. In addition, α-chymotrypsin has been used in chiral separations for some amino
acids that are not substrates for this enzyme (e.g., leucine and alanine) [3]. α-Chymotrypsin-based
CSPs have further been used to separate a series of enantiomeric and diastereomeric dipeptides [180].
In addition, amino acid derivatives and chiral compounds such as naproxen and aryloxyproionic acids
have been separated by using α-chymotrypsin-based CSPs [121].
4.3. Other Proteins
A number of other proteins have been considered as binding agents and CSPs for chromatography.
One example is ovomucoid, which is a glycoprotein found in egg whites and that contains three
homologous domains [118]. Ovomucoid columns have been used for chiral separations of a large
number of drugs and chiral solutes [28,118,164,181–184]. In one recent study, an ovomucoid-based CSP
was used with LC-MS/MS to separate and analyze the enantiomers of ondansetron and doxazosin in
human plasma and to give information on the pharmacokinetics of these agents [185,186].
Antibodies, which are glycoproteins that are produced by the immune system of vertebrates,
are another group of proteins that have been explored for use in chiral separations [187–193]. Various
anti-α-amino acid antibodies have been used as chiral agents to separate aromatic and aliphatic
amino acids (see Figure 6) [189,191,192]. Antibodies against α-hydroxy acids have been employed to
resolve the enantiomers of several α-hydroxy acids, including both aromatic and aliphatic compounds
(e.g., lactic acid) [193]. In one report, a monoclonal anti-D-hydroxy acid antibody was used to isolate
and analyze the enantiomers of lactic acid in human urine by using immunoaffinity chromatography
and LC-MS [190].
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Avidin is a glycoprotein that is obtained from egg whites and that can strongly bind to
biotin [194]. Avidin-based CSPs have been investigated for use with drugs and solutes that have
included thalidomide, glutethimide, premaquine, aminoglutethimide, and pyridoglutethimide [195].
In addition, this protein has been used in open tubular columns and in CEC for chiral
separations [99,100,106,196–198]. Avidin-based CSPs have also been prepared by immobilizing
this protein to a phospholipid coating or to magnetic particles in a fused silica capillary [106,197].
Chiral separations have been obtained with avidin in open tubular columns for a variety of chiral
compounds, including ketoprofen, flurbiprofen, ibuprofen, abscisic acid, chrysanthemic acid, warfarin,
tryptophan, omeprazole, and 5-hydroxyomeprazole [99,100,106,196–198].
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Streptavidin is a biotin-binding protein that is produced by the bacterium Streptomyces avidinii [20,26].
Streptavidin and avidin are both tetrameric proteins and have similar primary structures, but the
overall charges for these two proteins are quite different, with streptavidin having an isoelectric point
of 5 and avidin having a value of 10 [20,194]. Streptavidin has been employed as a CSP on a perfusion
support for separating adenosine enantiomers [199]. The role of the biotin binding sites in this process
was examined by chromatography, as well as the binding capacity for D- and L-adenosine and the
effects of sample concentration and temperature on solute retention [199].
5. Conclusions
The separation and analysis of chiral drugs has become important in both the discovery and
development of new pharmaceutical agents [7,9]. Chromatographic methods employing proteins as
chiral selectors have been found in recent years to be powerful tools for separating chiral drugs or
solutes and for examining their interactions with proteins [6,9,17–19]. This review gave an overview
of the chromatographic studies and applications that have involved protein-based chiral separations.
Several chromatographic approaches were discussed that have been used to characterize and examine
these separations, including zonal elution, frontal analysis, and kinetic methods of analysis. Supports
and immobilization methods that have been used to prepare protein-based CSPs were also summarized.
Finally, examples of proteins that have been considered for use in CSPs for chromatography, and the
applications of these proteins were considered. These proteins ranged from serum transport proteins
and enzymes to other proteins such as ovomucoid, antibodies, and avidin or streptavidin [17,18,20].
These protein-based CSPs have already been employed with a wide range of chiral drugs and solutes,
as was illustrated by the examples given within this review. It was also shown how chromatographic
methods have been used to provide valuable information for better characterizing and optimizing
these chiral separations [17,18,20]. Future work in this area and in the use of chromatography with
protein-based CSPs should lead to the continued development of improved chiral separations for drug
discovery or development and pharmaceutical research [9,82,97].
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